(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Dinosaur collagen used to create one-of-a-kind handbag - 2Former United Launch Alliance CEO Tory Bruno joins competitor Blue Origin for national security projects
- 3Pentagon advances Golden Dome missile defense with new Space Force contracts
- 4This Week In Space podcast: Episode 203 — China Rising
- 5A new mom skipped a routine appointment. An infected cut led to a devastating diagnosis
- The architect of Iran’s military survival remains defiant
- Like many holiday traditions, lighting candles and fireplaces is best done in moderation
- Revealing the Incomparable Realms: An Excursion through Power and Inheritance
- Sintana Energy flags major resource upgrade at Namibia oil discovery
- Accomplishing Balance between fun and serious activities: Procedures for a Better Life
- Go on A Careful spending plan: Modest Objections for Your List of must-dos
- The Delight of Perusing: Book Proposals for Each Class
- Instructions to Expand Your Advantages from an Open Record Reward
- Bonk.fun’s April Fools Joke Targets Israel, Sparks Debate
